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Abstract. Data from in vivo studies have indicated a role
for b-blockers in the prevention of bone loss. Some
epidemiological studies have found protective eﬀects of
b-blockers on fracture risk. However, there is limited
information on the association with cumulative dose
and type of b-blockers used. We conducted two case-
control studies using data from the UK General Practice
Research Database (GPRD) and the Dutch PHARMO
Record Linkage System (RLS). Cases were patients with
a ﬁrst hip or femur fracture; controls were individually
matched on practice/region, gender, year of birth, and
calendar time. Current use of b-blockers was deﬁned as
a prescription in 90 days before the index date. We ad-
justed for medical conditions and drugs associated with
falling or bone mineral density. Odds ratios (ORs) and
95% conﬁdence intervals (CIs) were calculated using
conditional logistic regression analysis. The study pop-
ulation included 22,247 cases and controls in the GPRD
and 6,763 cases and 26,341 controls in the PHARMO
RLS. Current use of b-blockers was associated with a
reduced risk of hip/femur fracture in both the GPRD
(adjusted OR = 0.82, 95% CI 0.740.91) and PHAR-
MO RLS (adjusted OR = 0.87, 95% CI 0.800.95)
study populations. However, this reduction of risk was
not associated with cumulative dose, lipophilicity, or
receptor selectivity of b-blockers. The protective eﬀect
of b-blockers was only present among patients with a
history of use of other antihypertensive agents (GPRD
adjusted OR = 0.72, 95% CI 0.640.83; PHARMO
RLS adjusted OR = 0.76, 95% CI 0.670.86) but not
in patients using b-blockers only (GPRD adjusted
OR = 0.97, 95% CI 0.821.14; PHARMO RLS ad-
justed OR = 1.01, 95% CI 0.901.14). Also, in patients
with a history of use of other antihypertensive agents, no
dose-response relationship with b-blocker use was
found. The eﬀect was constant with cumulative dose and
the OR was below 1.0 even among patients who just
started treatment with b-blockers. As the mechanism by
which b-blockers could inﬂuence bone mineral density is
likely to need some time to exert a clinically relevant
eﬀect, all these ﬁnding suggests that the association
between b-blockers and fracture risk is not causal.
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Bone remodeling comprises a phase of resorption by
osteoclasts and a phase of formation by osteoblasts.
Recent studies have shown bone metabolism to be
mediated through the autonomic central nervous sys-
tem. Leptin, a hormone produced in fat cells to signal
energy insuﬃciency, regulates bone remodeling by
modulating osteoblast proliferation and subsequent
osteoclast activation via the osteoclast diﬀerentiation
factor receptor activator of nuclear factor jB ligand
(RANKL). The antiosteogenic eﬀect of leptin is not
present in b2-adrenergic receptor-deﬁcient mice, which
had actual increases in bone mineral density (BMD)
[15]. Data from these in vivo studies indicate a role
for b-blockers in the prevention of bone loss. In the
early 1990s, propranolol was found to increase bone
formation [6]. Some observational studies have re-
ported that use of b-blockers was associated with a
decreased risk of fractures [79], conﬂicting with other
studies which found no association with fractures
[1012]. Studies on the eﬀects of b-blockers on sub-
clinical endpoints, like BMD or biochemical markers
of bone resorption, have also yielded inconsistent re-
sults [7, 10, 1214].
A possible role for b-blockers in the prevention of
fractures is of major clinical interest, given that fractures
are a major source of morbidity, disability, hospital-
ization, and mortality. One of the most serious fractures
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However, there is still a lack of knowledge with respect
to the eﬀects of cumulative dose and type of b-blockers
used. Thus, the objective of this study was to assess the
strength of the association between use of b-blockers
and risk of hip/femur fractures using data from two
diﬀerent large population-based databases in the United
Kingdom and The Netherlands.
Materials and Methods
Setting
Data for this study were obtained from the UK General
Practice Research Database (GPRD) and the Dutch PHAR-
MO Record Linkage System (RLS). The GPRD contains the
computerized medical records of general practices across
the United Kingdom (www.gprd.com). Approximately 6% of
the total registered population of England and Wales is rep-
resented in the database, and it includes a cumulative total of
over 5 million adult patients. The age and sex distribution of
patients enrolled is representative of the general English and
Welsh populations. Patient details accrued in the GPRD in-
clude demographic information, diagnoses, prescription de-
tails, preventive care provided, referrals to specialist care,
hospital admissions, and related major outcomes [16]. Clinical
data are stored and retrieved by means of Oxford Medical
Information Systems and Read codes for diseases or causes of
morbidity and mortality that are cross-referenced to the
International Classiﬁcation of Diseases (ICD-9). Several inde-
pendent validation studies have shown that the GPRD has a
high level of completeness and validity, including for hip
fractures [17, 18].
The PHARMO RLS includes the demographic details and
complete medication history of 950,000 community-dwelling
residents of more than 25 population-deﬁned areas in The
Netherlands from 1985 onward. It is further linked to hospital
admission records as well as several other health registries,
including pathology, clinical laboratory ﬁndings, and general
practitioner data (www.pharmo.nl). Since the majority of all
patients in The Netherlands are registered only with one
community pharmacy, independently of prescriber, pharmacy
records are virtually complete with regard to prescription
drugs. For this study, drug-dispensing and hospitalization data
were used. The computerized histories record information on
the type of drug dispensed, dispensing date, prescriber, amount
dispensed, and prescribed dosage regimen. Hospital discharge
records include detailed information on the primary and sec-
ondary discharge diagnoses; diagnostic, surgical, and treat-
ment procedures; type and frequency of consultations with
medical specialists; and dates of hospital admission and dis-
charge. All diagnoses are coded according to the ICD-9-CM
[19].
Deﬁnition of Cases and Controls
GPRD. A case-control study was conducted using GPRD
data collected from January 1987 to July 1999. The details of
this study have been described elsewhere [20, 21]. Brieﬂy,
cases were deﬁned as patients aged 18 years and older with a
ﬁrst record of a hospital admission for a hip/femur fracture
(ICD-9 codes 820821) recorded in their medical records
between the enrollment date of their practice in the GPRD
and the end of data collection. The date of the occurrence of
the hip/femur fracture was the index date. Each case was
matched by year of birth, sex, medical practice, and calendar
time to one control patient without a history of a fracture. If
no eligible control was available, the age criterion was ex-
panded consecutively at 1-yearly intervals to a maximum of
10 years. If no eligible control patient could be found, then
an age- and sex-matched control patient from another prac-
tice was selected.
PHARMO RLS. Cases were patients aged 18 years and older
with a ﬁrst admission for a hip/femur fracture between Jan-
uary 1, 1991, and December 31, 2002. The date of the hos-
pital admission was the index date. Up to four control
patients, who did not have a history of any type of fracture,
were matched to each case by year of birth, gender, region,
and calendar time.
Exposure Assessment
For each patient, we identiﬁed all prescriptions for (GPRD)
and dispensing of (PHARMO RLS) b-blockers prior to the
index date. Current users were deﬁned as patients who had a
prescription/dispensing for b-blockers within 3 months prior to
the index date. Recent users received a last prescription/dis-
pensing 36 months before the index date, past users 612
months before the index date, and distant past users more than
12 months before the index date. The last prescribed daily dose
prior to the index date was obtained from the written dosage
instructions. For each patient, cumulative exposure to
b-blockers ever before the index date was calculated. The eﬀect
of cumulative dose was assessed bothregardless of the timing of
use and stratiﬁed to current, recent, past, and distant past use.
Thus, current users could be classiﬁed to a low previous
cumulative exposure (e.g., one or two 30-day prescriptions) or a
high previous cumulative exposure (e.g., 100 30-day prescrip-
tions). The estimated daily dose for each class of b-blocker was
expressed as a fraction of the World Health Organization de-
ﬁned daily dose (DDD). A DDD is deﬁned as the assumed
average maintenance dose per day for a drug if used for its main
indication in adults [22]. DDD equivalents can be used to
compare drugs within a certain therapeutic group. In this study,
we converted the DDD equivalents to milligrams of metopro-
lol, similar to the approach used in previous studies [21]. Fur-
thermore, b-blockers were categorized according to receptor
selectivity and lipophilicity based on data in handbooks on
clinical pharmacology and therapeutics.
Statistical Analysis
The strength of the association between use of b-blockers and
risk of hip/femur fractures was estimated using conditional
logistic regression analysis (SAS version 9.1.3, PHREG pro-
cedure; SAS Institute, Cary, NC) and expressed as odds ratios
(ORs) and 95% conﬁdence intervals (CIs). Final regression
models were determined by stepwise backward elimination
using a signiﬁcance level of 0.05. Smoothing spline regression
plots were used to visualize the eﬀect of cumulative b-blocker
dose on risk of hip/femur fractures [23].
In our analysis, we controlled for a wide range of clinical
variables that have been associated with risk of falls or
fractures. In the GPRD study, we included the following
variables in the ﬁnal model: history of diabetes mellitus,
rheumatoid arthritis, hyperthyroidism, congestive heart fail-
ure, seizures, anemia, dementia, depression, psychotic disor-
der, cerebrovascular accident, chronic obstructive pulmonary
disease, osteoporosis, and a record of back pain or falls in the
year before the index date. Furthermore, prescriptions, in the
6 months prior to the index date, for anticonvulsants, non-
steroidal anti-inﬂammatory drugs (NSAIDs), methotrexate,
hormone replacement therapy, other hypertensive drugs (low-
ceiling diuretics, renin-angiotensin-aldosterone system
[RAAS] inhibitors, calcium channel blockers), anxiolytics/
hypnotics, antipsychotics, antidepressants, anti-Parkinson
drugs, oral and inhaled glucocorticoids, and bronchodilators
as well as information on body mass index (BMI) were re-
tained in the model. In the PHARMO RLS study, variables
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zodiazepines in the 3 months prior to the index date, or, in
the 6 months prior to the index date, a dispensing of oral
glucocorticoids, inhaled glucocorticoids, bronchodilators,
statins, BMD-modifying drugs, hormone replacement ther-
apy, antipsychotics, antidepressants, opioids, antiepileptics,
other hypertensive drugs (low-ceiling diuretics, RAAS inhib-
itors, calcium channel blockers), antidiabetics, laxants, dis-
ease-modifying antirheumatic drugs, NSAIDs, or
metoclopramide. A history of hospital admission for cere-
brovascular disease, cancer, endocrine disorders, inﬂamma-
tory bowel disease and other bowel diseases, obstructive
airway disease, musculoskeletal and connective tissue dis-
eases, anemia, and skin diseases prior to the index date were
also included in the ﬁnal model.
Results
The study population in the GPRD comprised 22,247
cases and 22,247 controls, whereas in the PHARMO
RLS 6,763 cases and 26,341 controls were identiﬁed.
The characteristics of both populations are displayed in
Table 1. The sex and age distributions of cases were
similar in the two case-control sets, although more cases
in the GPRD set were aged over 80 years.
Current use of b-blockers was associated with a sig-
niﬁcantly decreased risk of hip/femur fracture in both
databases, whereas recent and past use was not (Ta-
ble 2). Adjusted ORs for current b-blocker users were
0.83 (95% CI 0.750.92) in the GPRD and 0.87 (95% CI
0.800.95) in the PHARMO RLS. There was no strong
eﬀect of cumulative dose among current users of
b-blockers in either data set (Fig. 1), while assessing the
eﬀect cumulative dose irrespective of timing of use
yielded similar results.
The most frequently prescribed b-blocker in the
GPRD was atenolol (3.0% among cases vs. 4.0%
among controls, adjusted OR = 0.80, 95% CI
0.710.90). Current use of other b-blockers was
infrequent (propranolol 0.4% vs. 0.5%, metoprolol
0.2% vs. 0.2%) and not associated with a decreased risk
of hip/femur fracture (adjusted OR = 0.90, 95% CI
0.761.06). In the PHARMO RLS, the most fre-
quently used b-blockers at the index date were meto-
prolol (4.6% among cases vs. 5.6% among controls),
atenolol (3.2% vs. 3.6%), sotalol (1.9% vs. 1.5%), and
propranolol (0.9% vs. 0.9%). The adjusted ORs for
current use of metoprolol and atenolol were 0.79 (95%
CI 0.690.90) and 0.89 (95% CI 0.771.04), respec-
tively. Current use of propranolol (adjusted
OR = 0.98, 95 CI 0.741.21) and sotalol (adjusted
OR = 1.15, 95% CI 0.931.42) were not associated
with a protective eﬀect of hip/femur fracture.
Categorizing b-blockers according to their lipophi-
licity, receptor selectivity, or last prescribed daily dose
did not reveal major diﬀerences in eﬀect (Table 2), nor
did stratiﬁcation according to age and gender (Table 3).
The protective eﬀect of b-blockers was only present
among patients who had been treated with other
antihypertensive agents (e.g., low-ceiling diuretics,
calcium antagonists, RAAS inhibitors), either concur-
rently or in the past (Table 3). This ﬁnding was con-
sistent in both the GPRD (adjusted OR = 0.73, 95%
CI 0.640.83) and PHARMO RLS (adjusted
OR = 0.76, 95% CI 0.670.86). Among patients
using only b-blockers, the adjusted ORs were close to
unity. In both data sets, the interaction term between
Table 1. Characteristics of hip/femur fracture cases and controls in the GPRD and PHARMO RLS
Characteristic
GPRD PHARMO RLS
Cases
(n = 22,247)
Controls
(n = 22,247)
Cases
(n = 6,763)
Controls
(n = 26,341)
Gender
Women 75.8% 75.8% 72.9% 72.7%
Age (years)
<65 13.9% 13.9% 15.8% 16.2%
6579 30.8% 32.2% 36.6% 37.3%
‡80 55.2% 53.9% 47.6% 46.5%
Smoking
a 22.1% 20.6% No data available
BMI
b
2025 46.6% 42.4%
<20 18.0% 9.7% No data available
>25 35.4% 47.9%
Antidepressants 13.0% 7.2% 9.5% 5.1%
Oral glucocorticoids 7.2% 4.4% 5.4% 3.5%
Thiazides 11.9% 12.9% 12.1% 11.4%
Nitrates 6.9% 7.4% 9.4% 9.1%
Hormone replacement 0.6% 1.2% 1.1% 1.3%
a No data on smoking status for 45% of GPRD study population
b No data on BMI for 58.5% of GPRD study population
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tensive drugs was statistically signiﬁcant (P < 0.05).
Furthermore, no eﬀect of cumulative dose was found
in either current users of b-blocker only or in current
b-blocker users with a history of using other antihy-
pertensive drugs (Fig. 2). Further stratiﬁcation
according to high or low average daily dose during
the study period indicated no eﬀect of the intensity of
b-blocker use on the risk estimates.
Discussion
In both the GPRD and PHARMO RLS data sets,
current use of b-blockers was associated with a de-
creased risk of hip/femur fractures. However, there was
no reduced risk of hip/femur fractures among patients
who did not have a history of using other antihyper-
tensive drugs: a protective eﬀect of b-blockers was only
observed for patients with current or prior use of other
antihypertensive agents. Even within this group of pa-
tients, no dose-response relationship with b-blocker use
was found. The eﬀect was constant with cumulative dose
and the OR was below 1.0 even among patients who had
just started treatment with b-blockers. As the mecha-
nism by which b-blockers could inﬂuence BMD is likely
to need some time to exert a clinically relevant eﬀect,
this ﬁnding suggests that the association between
b-blockers and fracture risk is not causal.
Based on in vivo and in vitro studies and the dis-
covery that the central nervous system is involved in
the regulation of bone, b-blockers have been impli-
cated in a preventive role in patients with osteoporosis.
Central eﬀects of leptin have been found to be medi-
ated by the sympathetic nervous system, acting via b
receptors on osteoblasts [3]. b agonists stimulate bone-
resorption activity in osteoclasts [24]. Previous data
have shown that systemic application of b agonists
had a negative eﬀect on bone mass in mice [25],
whereas b antagonists stimulated bone formation in
rats [6].
Table 2. Use of b-blockers and risk of hip/femur fracture in the GPRD and PHARMO RLS
b-blocker exposure
GPRD PHARMO RLS
Cases
(%)
Controls
(%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Cases
(%)
Controls
(%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Timing of use
Current use 4.5 5.9 0.70 (0.640.77) 0.82 (0.740.91) 12.4 13.7 0.91 (0.830.98) 0.87 (0.800.95)
Recent use 0.6 0.6 0.89 (0.701.14) 0.88 (0.681.15) 1.7 1.7 1.01 (0.821.24) 0.93 (0.751.15)
Past use 0.7 0.6 1.10 (0.861.40) 0.99 (0.761.28) 1.4 1.3 1.11 (0.881.40) 0.99 (0.781.26)
Distant past use 3.7 2.8 1.10 (0.981.22) 1.06 (0.941.20) 6.8 6.3 1.07 (0.961.20) 0.97 (0.871.09)
Among current users of b-blockers
Selectivity
Low 1.0 1.2 0.75 (0.630.90) 0.86 (0.711.05) 3.5 3.1 1.12 (0.971.30) 1.04 (0.891.21)
Medium 0.1 0.2 0.79 (0.481.32) 0.81 (0.471.41) 0.3 0.5 0.40 (0.200.84) 0.38 (0.180.79)
High 3.3 4.4 0.69 (0.620.76) 0.77 (0.690.87) 8.7 10.1 0.86 (0.790.95) 0.84 (0.760.93)
Lipophilicity
Hydrophile 3.2 4.2 0.69 (0.620.77) 0.78 (0.700.88) 5.1 5.2 0.98 (0.861.11) 0.94 (0.831.06)
Intermediate 0.2 0.2 0.77 (0.501.20) 0.88 (0.561.39) 0.5 0.4 1.15 (0.771.73) 1.04 (0.691.58)
Lipophile 1.1 1.4 0.72 (0.600.85) 0.81 (0.680.98) 6.9 8.0 0.85 (0.770.95) 0.83 (0.740.92)
First prescription
Yes 0.2 0.2 0.93 (0.581.48) 1.18 (0.691.99) 0.4 0.6 0.63 (0.420.95) 0.62 (0.410.94)
Last prescribed daily dose (DDD)
b
<0.67 0.9 1.2 0.72 (0.590.87) 0.81 (0.651.00) 8.7 9.8 0.89 (0.810.98) 0.87 (0.790.96)
0.671.33 2.0 2.6 0.73 (0.640.83) 0.85 (0.740.99) 3.2 3.4 0.95 (0.821.11) 0.90 (0.771.06)
>1.33 1.4 2.0 0.64 (0.550.75) 0.81 (0.690.97) 0.4 0.4 0.95 (0.611.49) 0.85 (0.541.35)
a Adjusted for use of other antihypertensive drugs and general risk factors for falls and fractures (see Materials and Methods)
b One DDD is equivalent to 150 mg metoprolol
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Fig. 1. Spline visualization of cumulative dose among current
ß-blocker users and risk of hip/femur fractures (GPRD, dashed
line, solid circles; PHARMO RLS, solid line, open circles).
Cumulative dose is expressed in DDDs (1,000 DDDs are
equivalent to 150 g of metoprolol). Odds ratios were adjusted
for the same confounders as in Table 2.
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crepant results on the association between use of
b-blockers and risk of fracture [712], including a study
that also used data from the GPRD [8]. The reason for
the discrepancy is unclear. Emerging data from ran-
domized controlled trials also support a lack of eﬀect of
b-blockers on the risk of fracture. Recently, a clinical
trial among 41 normal postmenopausal women found
no evidence that propranolol stimulates bone formation,
as measured by bone turnover markers [26]. Further-
more, pooled data from nine clinical trials investigating
the nonselective b-blocker carvedilol in the management
of congestive heart failure did not provide evidence in
support of an eﬀect of b-blockers on fracture risk
reduction [10]. The data from this meta-analysis are
consistent with the results of our study as no eﬀect on
fracture was observed in patients treated with b-blockers
without history of other antihypertensive drug use.
Therapeutic uses of b-blockers include the treatment
of hypertension as well as heart failure and secondary
prevention post-myocardial infarction, -cardiac dys-
rhythmia, and -angina pectoris. Cardiovascular disease,
heart failure, and hypertension have all been linked with
decreased BMD [2730]. Because thiazides, calcium
channel blockers, and inhibitors of the renin-angiotensin
system have also been associated with beneﬁcial eﬀects
on bone [31], we stratiﬁed in our study on history of use
of other antihypertensive drugs to separate the eﬀect of
current use of b-blockers from that of other antihyper-
tensive agents. This method of stratiﬁcation was not
applied in earlier epidemiological studies on b-blockers
and fractures.
The strength of our study is that it was population-
based. Furthermore, we found the same results in
both the UK and Dutch data sets. The prevalence of
b-blocker use was nearly three times as high in the
PHARMO RLS compared to the GPRD. In 2002, 5.1
million prescriptions for b-blockers were issued in The
Netherlands (population 16 million) [32] compared to
22.4 million prescriptions in the United Kingdom in the
Table 3. Current use of b-blockers and risk of hip/femur fractures in patient subgroups
Current use of
b-blockers
GPRD PHARMO RLS
Cases
(%)
Controls
(%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Cases
(%)
Controls
(%)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
a
Gender
Men 3.4 4.5 0.68 (0.550.84) 0.77 (0.600.98) 10.1 12.0 0.83 (0.700.98) 0.77 (0.640.93)
Women 4.8 6.3 0.71 (0.640.78) 0.83 (0.740.93) 13.3 14.4 0.93 (0.951.02) 0.90 (0.821.00)
Age (years)
<65 2.9 3.1 0.93 (0.681.26) 0.91 (0.620.91) 5.0 7.2 1.04 (0.801.35) 0.94 (0.701.27)
6580 7.0 9.1 0.71 (0.620.80) 0.84 (0.730.98) 14.5 16.8 0.84 (0.581.12) 0.80 (0.700.91)
80+ 3.5 4.6 0.65 (0.570.75) 0.77 (0.660.91) 12.4 13.5 0.94 (0.841.06) 0.94 (0.831.07)
History of any use of other antihypertensive drugs
No 2.2 2.4 0.89 (0.771.04) 0.97 (0.821.14) 8.3 8.1 1.02 (0.851.23) 1.01 (0.901.14)
Yes 9.7 14.7 0.60 (0.530.67) 0.73 (0.640.83) 20.9 26.9 0.73 (0.650.83) 0.76 (0.670.86)
a Adjusted for use of other antihypertensive drugs and general risk factors for falls and fractures (see Materials and Methods)
Percentages represent the proportion of current beta-blocker within each subcategory (e.g. male gender)
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Fig. 2. Spline visualization of cumulative dose among current
ß -blocker users, stratiﬁed according to patients not having (A)
or having a history of other antihypertensive drugs (B)
(GPRD, dashed line, solid circles; PHARMO RLS, solid line,
open circles). Cumulative dose is expressed in DDDs (1,000
DDDs are equivalent to 150 g of metoprolol). Odds ratios
were adjusted for the same confounders as in Table 2, except
for the use of antihypertensive drugs.
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count that prescriptions in the United Kingdom are
usually for 30 days and those in The Netherlands for 90
days, we can conclude that the observed diﬀerence in
exposure prevalence is in line with prescribing data
volumes in both countries.
Observational studies like ours have potential for
bias and confounding and can fuel debates on study
interpretation and credibility [3436]. Various drugs
with eﬀects on the central nervous system are known to
increase the risk of falls and thereby fracture risk. Also,
there are likely to be complex interactions between
vascular disease and fracture risk, operating through
falls risk, BMD, or common genetic or lifestyle factors.
In this study, we had no information on BMD and we
cannot exclude the possibility that cases and controls
were diﬀerent with respect to BMD. However, given
that initiation of antihypertensive treatment in daily
clinical practice will usually be independent of patient
BMD, major confounding seems unlikely. Variables
included in the ﬁnal regression models were slightly
diﬀerent between the two data sets due to the nature of
the data collections. However, multivariate adjustment
had only modest eﬀects on the OR of the exposure of
interest. Information on smoking and BMI was not
available in the PHARMO RLS database, but adjust-
ment for these factors in the GPRD had no inﬂuence
on risk estimates (smoking was not retained in the
model). Data on BMI were missing for 58% of the
GPRD study population, so we cannot exclude the
concern that adjustment was suboptimal. We had no
data on physical activity, diet, or socioeconomic status
as such information is not available in the databases
used in our studies [37]. Furthermore, we cannot ex-
clude the possibility that residual confounding can ex-
plain part of our results.
An alternative explanation for our ﬁndings could be
that the protective eﬀect of b-blockers on fractures is an
artifact caused by selective underuse in patients with an
unmeasured comorbidity, a problem that has been de-
scribed by Glynn et al. in a study on cardiovascular drug
use and mortality [38]. In their study, among elderly
subjects in the United States, they found that users of
drugs from seven commonly prescribed therapeutic
classes, including b-blockers, thiazide diuretics, and
angiotensin-converting enzyme inhibitors, had reduced
rates of death compared to nonusers, which was
more likely to be explained by selective prescribing and
nonadherence.
A potential limitation is that we conﬁned our study to
hip/femur fractures and did not evaluate other type of
fractures. It is possible that potential beneﬁcial eﬀects of
b-blockers are present only at sites other than the hip/
femur, but there is no evidence to support this.
In conclusion, the reduction in hip/femur fracture
risk was not related to cumulative dose of b-blockers
and was only present in patients using b-blockers with a
history of using other antihypertensive drugs as well.
This suggests that the eﬀect of b-blockers on hip/femur
fracture is not causal.
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